These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7783285)

  • 21. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
    Sato Y; Sato H
    Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization.
    Hawken S; Manuel DG; Deeks SL; Kwong JC; Crowcroft NS; Wilson K
    Am J Epidemiol; 2012 Dec; 176(11):1035-42. PubMed ID: 23118103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments with pertussis vaccines.
    Halsey NA; Peter G
    Pediatrics; 1995 Nov; 96(5 Pt 1):970-1. PubMed ID: 7478849
    [No Abstract]   [Full Text] [Related]  

  • 24. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
    Mallet E; Puyt A; Arson S; Surbled V
    Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA approval of a second acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Feb; 46(5):110-1. PubMed ID: 9045038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune responses to pertussis vaccines and disease.
    Edwards KM; Berbers GA
    J Infect Dis; 2014 Apr; 209 Suppl 1():S10-5. PubMed ID: 24158958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Swedish efficacy trial of acellular pertussis vaccines--update and time for reflection.
    Olin P
    Dev Biol Stand; 1991; 73():33-6. PubMed ID: 1778327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of recent clinical trials of acellular pertussis vaccines.
    Miller E
    Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adult immunization with acellular pertussis vaccine.
    Edwards KM; Decker MD; Graham BS; Mezzatesta J; Scott J; Hackell J
    JAMA; 1993 Jan; 269(1):53-6. PubMed ID: 8416406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines.
    Lancet; 1988 Apr; 1(8592):955-60. PubMed ID: 2896826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acellular pertussis vaccines].
    Finger H; Wirsing von König CH
    Immun Infekt; 1992 Dec; 20(6):188-91. PubMed ID: 1490723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and serological reactions after immunization of children in Ghana, West Africa, with the Japanese acellular pertussis vaccine.
    Biritwum RB; Isomura S; Ofosu-Amaah S; Sato Y
    Dev Biol Stand; 1985; 61():539-43. PubMed ID: 2872130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial].
    Kallings LO; Olin P; Storsaeter J
    Lakartidningen; 1988 Jun; 85(22):1994-6. PubMed ID: 3287070
    [No Abstract]   [Full Text] [Related]  

  • 38. Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?
    Granoff DM; Rappuoli R
    Dev Biol Stand; 1997; 89():379-89. PubMed ID: 9272376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acellular pertussis trial.
    Hewlett EL
    Pediatrics; 1996 Oct; 98(4 Pt 1):800. PubMed ID: 8885972
    [No Abstract]   [Full Text] [Related]  

  • 40. A placebo-controlled trial of a pertussis-toxoid vaccine.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
    N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.